Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gravis (gMG) was selected as an...
Sunway Medical Centre named Top Malaysian Smart Hospital in Newsweek’s World’s Best Smart Hospitals 2026 ranking
SUNWAY CITY, Malaysia, Sept. 18, 2025 /PRNewswire/ -- Sunway Medical Centre, Sunway City (SMC) has been honoured as top Malaysian hospital and debuted in the top 350 hospitals in the world, as per the latest Newsweek's World's Best Smart Hospitals 2026 ranking. Overview of Sunway Medical Centre, Sunway City. This is the first...
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
SHANGHAI, Sept. 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targeting BCMA) have been presented as...
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology...
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to placebo: 58.6% versus 56.3%. The majority of TEAEs were mild (Grade 1) or moderate (Grade...
MagicRNA’s First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients. Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of circulating B cells and up to 20-points reduction in patient's SLEDAI scores within three months....
Dornier MedTech America launches Hoover™ and AXIS® II SLIM, raising the bar in kidney stone treatment
KENNESAW, Ga., Sept. 17, 2025 /PRNewswire/ -- Dornier MedTech America (DMTA) has announced the full U.S. commercial launch of its Dornier Hoover Flexible and Navigable Suction Ureteral Access Sheath (FANS) and Dornier Axis II Slim single-use ureteroscope with a 5.6Fr. distal tip. Dornier Hoover Optivision Already FDA-cleared...
NYSE Content Advisory: Pre-Market Update + Fed decision & StubHub celebrates IPO
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Fed decision & StubHub celebrates IPO...
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile SKY-0515's Phase 2/3 FALCON-HD trial in patients in Australia and New Zealand is ongoing ...
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 /PRNewswire/ -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular...
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary,...
